These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2908626)

  • 1. Antibody-toxin conjugation.
    Marsh JW; Srinivasachar K; Neville DM
    Cancer Treat Res; 1988; 37():213-37. PubMed ID: 2908626
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins.
    Wawrzynczak EJ; Thorpe PE
    Cancer Treat Res; 1988; 37():239-51. PubMed ID: 2908627
    [No Abstract]   [Full Text] [Related]  

  • 3. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
    Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
    J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents.
    Lau A; Bérubé G; Ford CH
    Bioorg Med Chem; 1995 Oct; 3(10):1299-304. PubMed ID: 8564395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates.
    Zara JJ; Wood RD; Boon P; Kim CH; Pomato N; Bredehorst R; Vogel CW
    Anal Biochem; 1991 Apr; 194(1):156-62. PubMed ID: 1867379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
    Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
    Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oriented and covalent immobilization of target molecules to solid supports: synthesis and application of a light-activatable and thiol-reactive cross-linking reagent.
    Collioud A; Clémence JF; Sänger M; Sigrist H
    Bioconjug Chem; 1993; 4(6):528-36. PubMed ID: 7508269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of cytotoxic antibody-toxin conjugates.
    Cumber AJ; Wawrzynczak EJ
    Methods Mol Biol; 1998; 80():135-44. PubMed ID: 9664370
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
    Wakankar AA; Feeney MB; Rivera J; Chen Y; Kim M; Sharma VK; Wang YJ
    Bioconjug Chem; 2010 Sep; 21(9):1588-95. PubMed ID: 20698491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies.
    Alonso CM; Palumbo A; Bullous AJ; Pretto F; Neri D; Boyle RW
    Bioconjug Chem; 2010 Feb; 21(2):302-13. PubMed ID: 20073477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma.
    Rosenblum M
    Adv Pharmacol; 2004; 51():209-28. PubMed ID: 15464911
    [No Abstract]   [Full Text] [Related]  

  • 13. A new 'solid phase' procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates).
    Dosio F; Brusa P; Delprino L; Ceruti M; Grosa G; Cattel L; Bolognesi A; Barbieri L
    Farmaco; 1993 Jan; 48(1):105-15. PubMed ID: 8457275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin.
    Avila AD; Calderón CF; Pérez RM; Pons C; Pereda CM; Ortiz AR
    Biol Res; 2007; 40(2):173-83. PubMed ID: 18064354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and photoactivation of caged fluorophores and caged proteins using a new class of heterobifunctional, photocleavable cross-linking reagents.
    Ottl J; Gabriel D; Marriott G
    Bioconjug Chem; 1998; 9(2):143-51. PubMed ID: 9548528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
    Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L
    Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of immunotoxins: current progress and future prospects.
    Wawrzynczak EJ
    Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal modification of immunoglobulin polypeptide chains tagged with isothiocyanato chelates.
    Rana TM; Meares CF
    Bioconjug Chem; 1990; 1(5):357-62. PubMed ID: 2129106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifunctional reagents.
    Ji TH
    Methods Enzymol; 1983; 91():580-609. PubMed ID: 6855603
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotoxins containing single-chain ribosome-inactivating proteins.
    Lambert JM; Blättler WA; McIntyre GD; Goldmacher VS; Scott CF
    Cancer Treat Res; 1988; 37():175-209. PubMed ID: 2908625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.